Skip To Main Content
Fiyinfolu Balogun on Muck Rack

Fiyinfolu Balogun

As seen in: Nature, JAMA Network, JAMA Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Fiyinfolu

Contact Fiyinfolu, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Maximal Ablative Irradiation Because of Encasement for Patients With Locally Advanced Pancreatic Cancer : A Nonrandomized Clinical Trial

|
By Marsha Reyngold, Alice C Wei, Eileen M. O’Reilly, Michael I. D’Angelica, T. Peter Kingham, Kevin C. Soares, Anna Varghese, Charlie White, Melissa Zinovoy, Paul B Romesser, Abraham J. Wu, Carla Hajj, John Cuaron, Danny N. Khalil, Fiyinfolu Balogun, Wungki Park, Vinod P. Balachandran, Jeffrey Drebin, Maria Divina LaGratta, Zhigang Zhang, William R. Jarnagin, Christopher H. Crane
| JAMA Network Verified
Maximal Ablative Irradiation Because of Encasement for Patients With Locally Advanced Pancreatic Cancer: A Nonrandomized Clinical Trial Key Points Question For patients with locally advanced pancreatic cancer (LAPC) with extensive arterial and venous involvement after standard chemotherapy, is ablative radiation therapy (A-RT) associated with better resectability and overall survival without undue toxicity?
Open in Who Shared Issue with article?

Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial

|
By Wungki Park, Catherine A. O’Connor, Joanne F. Chou, Marc Hilmi, Zeynep Tarcan, Carly Schwartz, Mary Larsen Verified, Karthigayini Sivaprakasam, Shigeaki Umeda, Maria Perry, Anna Varghese, Fiyinfolu Balogun, Alice Zervoudakis, Seth Katz, Tae-Hyung Kim, Ken Zhao, Allison Richards, Nicolas Lecomte, Daniel Muldoon, Walid K. Chatila, Jessica Yang, Devika Rao Verified, Smita Joshi, Michael Foote, James Harding Verified, Andrew Epstein, David P. Kelsen, Fergus Keane, Joshua D. Schoenfeld, Anupriya Singhal, Erin DiGuglielmo, Chaitanya Bandlamudi, Junmin Song, Haochen Zhang, Maria Teresa Lao, Jerry P Melchor, Ronak Shah, Wenfei Kang, Francesca Mazzoni, Kevin C. Soares, Ernesto Santos, Vineet S. Rolston, Marsha Reyngold, Alice Wei, Murray J. Tipping, Olca Basturk, Michael Berger, Mark Schattner, William R. Jarnagin, Nadeem Riaz, Vinod P. Balachandran, Dana Pe’er, Marinela Capanu, Eileen M. O’Reilly, Ramzi Homsi, Elias Karnoub, Imane El-Dika, Ryan Sugarman, Sree Chalassani, Hulya Sahin Ozkan, Junguei Hong, Agustin III Cardenas, Mark TA Donoghue, Richard Kihn Do, Christine Iacobuzio-Donahue
| Nature Verified
Abstract Homologous recombination deficiency (HRD) arising from BRCA1or BRCA2 or PALB2 mutations confers sensitivity to platinum chemotherapy and PARP inhibition in pancreatic cancer (PC) and may enable prolonged disease control with immune checkpoint blockade (ICB). The phase 2 POLAR trial evaluated maintenance pembrolizumab plus olaparib following platinum-based chemotherapy in biomarker-stratified metastatic PC.
Open in Who Shared Issue with article?

When Radiotherapy and Immunotherapy Dance-Who Leads So as Not to Step on Toes?

|
By David Raben, Fiyinfolu Balogun
| JAMA Oncology Verified
Original Investigation Association of Radiation Therapy With Risk of Adverse Events in Patients Receiving Immunotherapy Mitchell S. Anscher, MD; Shaily Arora, PharmD; Chana Weinstock, MD; Anup Amatya, PhD; Pradeep Bandaru, PhD; Chad Tang, MD; Andrew T. Girvin, PhD; Mallorie H. Fiero, PhD; Shenghui Tang, PhD; Rachael Lubitz, BA; Laleh Amiri-Kordestani, MD; Marc R. Theoret, MD; Richard Pazdur, MD; Julia A. Beaver, MD Full Text Full Text
Open in Who Shared Issue with article?
See all 3 articles